Our finding that treatment with C11 improved motor and cognitive behavior in Cdkl5 KO mice suggest that dual GSK-3β/HDAC6 inhibitors might be an effective treatment option for CDD. The gene discussed is CDKL5; the disease is craniodiaphyseal dysplasia.